Baylor College of Medicine

Genetronics, Inc.

Vgx Pharmaceuticals, Inc.

Ronald V Abruzzese

Bert W O'Malley

Ruxandra Draghia-Akli

Douglas R Kern

Sophia Yang Tsai

Jason Fewell

Vidya Mehta

Jeffrey L Nordstrom

Jason G Fewell

Bert W O'malley

Sophia Y Tsai

Disclosed is a novel inducible expression system characterized by undetectable biological effect in the absence of an inducer, but which exhibits efficient inducibility in the presence of an inducer.

Gene switch systems employing regulators with decreased dimerization

One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5' untranslated region ('UTR'); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.

Codon optimized synthetic plasmids

Growing community of inventors

The Woodlands, TX, United States of America

Ronald V Abruzzese